Overall, our findings highlight the crucial role of TIR domain complex acetylation activating TLR4/MAL/MyD88 signal pathway in the regulation of inflammatory immune response, and suggest that the inhibition of acetylation could serve as a novel therapeutic target for patients with infectious and autoimmune diseases. This evidence concerns the gene MYD88 and autoimmune disease.